India, July 8 -- MAIA Biotechnology Inc. (MAIA), a clinical-stage biopharmaceutical company, on Wednesday released encouraging efficacy data from the Part C expansion of the Phase 2 THIO-101 trial for Ateganosine in treating non-small cell lung cancer.
Ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) is an investigational, first-in-class telomere-targeting agent developed for the treatment of non-small cell lung cancer (NSCLC). Cancer cells often harbor telomeres with immunity against degradation, contributing to their continued survival and resistance to current chemotherapies. The drug targets these telomeres with an immune reaction, leading to tumor regression.
The current Phase 2 study is evaluating Ateganosine as a third-lin...